Abstract: This article presents a closed-form variable-structure control strategy with dual avoidance regions design for collision-free waypoint navigation and trajectory tracking of car-like vehicles ...

You might be staring at your budget, wondering how you’re supposed to cover rent, debt, and everything else on $20–$25 an ...

Abstract: This letter proposes an algorithm for solving finite-time nonlinear optimal control problems. The proposed method employs the Gauss pseudospectral method to transform the optimal control ...

Chinese AI startup’s release is a major update to its open-source model series, aimed at multi-language programming and ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...